ISSCA launched its first regenerative medicine training in Hormonal Modulation and Gynecology
Miami, Florida – The International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group (GSCG), successfully launched its inaugural training course in Hormonal Modulation and Gynecology, marking a significant milestone in the field of regenerative medicine. The course, held from June 10-12, 2023, in Cancun, Mexico, generated immense enthusiasm among participants as the Global Stem Cell Group demonstrated its commitment to disseminating cutting-edge training and information to medical professionals worldwide.
Led by a Well-Respected Doctor
Under the guidance of Dr. Jorge Alberto Elias, a renowned Gynecologist and Urogynecologist with over a decade of experience in Cellular Therapies, participants had the privilege of learning from a highly respected expert in the field. His expertise ensured that attendees received valuable and up-to-date information, enhancing the quality of their educational experience.
The event was divided between two esteemed venues, with the theoretical portion taking place at the Four Points Hotel, and the hands-on training conducted at the prestigious Cellular Hope Institute.
ISSCA commitment to advancing regenerative medicine was further demonstrated by the inclusion of over 30 doctors who joined the event remotely, accessing the conferences and the live proceedings through online channels. This approach enabled medical professionals worldwide to be part of the educational experience, even if they couldn’t attend in person. By embracing technology, the company expanded the reach of knowledge dissemination and fostered a global community of practitioners dedicated to staying at the forefront of regenerative medicine.
The training program focused on equipping doctors and medical professionals with the latest advancements in regenerative medicine, with a specific emphasis on gynecology. Participants delved into the cutting-edge techniques and breakthrough procedures that are shaping the field.
Three Days of Intense Learning
The three-day program was divided into theoretical sessions and hands-on practical training. The theoretical portion took place at the Four Points Hotel, where participants delved into the intricacies of hormonal modulation and its application in gynecology. Dr. Silvina Pastrana, director of ISSCA education in Latam, complemented the program with a session on Exosomes, stem cells, and automatic closed processing techniques using the GCell machine, providing a comprehensive overview of the latest advancements.
During the practical segment, participants convened at the Cellular Hope Institute, where they were immersed in real-life scenarios and witnessed the application of regenerative measures in gynecological cases. Seven diverse cases were presented, including Labiaplasty, Perineum Vaginoplasty, Lichen Sclerosus, Liposuction Mount of Venus, and Lipo fat transfer with open and closed techniques. Through these hands-on demonstrations, attendees gained practical skills and insights into utilizing regenerative medicine to enhance patients’ quality of life.
Reflecting on the success of the event, Benito Novas, Head of Public Relations for the International Society for Stem Cell Application, expressed his enthusiasm, stating, “We are delighted to further expand the ISSCA faculty and specialty areas, opening the door for all physicians to utilize the latest Regenerative Medicine technologies in their area of expertise. Our goal is to provide the best education and training in regenerative medicine and cellular therapies so that professionals can offer the highest quality care to their patients.”
ISSCA celebrates the tremendous success of this inaugural regenerative medicine training course and remains committed to expanding access to the latest knowledge and advancements in the field. By empowering medical professionals globally, ISSCA aims to help patients worldwide benefit from the latest strategies and breakthroughs in regenerative medicine.
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and regenerative medicine.
ISSCA updates its members on advances in stem cell research, MSC, exosomes, and regenerative medicine
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
The international community provides a platform for practitioners to interact with scientists and build medical networks necessary for marketing.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities worldwide. The goal is to encourage more physicians to practice regenerative medicine and make it available to patients nationally and internationally. Incorporated under the Republic of Korea as a non-profit company, the ISSCA is focused on fostering excellence and standards in regenerative medicine.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
Global Stem Cells Group Announces the Opening of a Multi-Specialty Regenerative Medicine Center in Cancun
Global Stem Cells Group has just announced the official opening of a new multi-specialty regenerative medicine center in Cancun. The new center is intended to incorporate different treatments based on regenerative medicine as well as to serve as a multi-specialty training center in the field of regenerative medicine and cellular therapies, offering doctors and patients the most advanced treatments in cell therapy worldwide.
The Cellular Hope Institute, as this facility was named, will also strive to pursue several objectives that will benefit patients and medical experts worldwide. It is expected to be a medical hub that will offer the best treatments for patients suffering from multiple conditions such as autoimmune deficiencies, sports injuries, chronic degenerative diseases and pediatric diseases.
Benito Novas says. “Our goal is to solve the problem and alleviate the condition, not just attempt to treat it. We are committed to offering top-notch technology available and quality care, emphasizing that our patients are always our number one priority. Our highly qualified team of experts are always ready to assist you at Cellular Hope Institute.”
The Center utilizes comprehensive stem cell treatment protocols that employ well-targeted combinations of Exosomes, allogeneic human Mesenchymal cells, autologous bone marrow and Adipose derived stem cells to treat the diseases and conditions listed above. The treatment plans are mostly focused on a systemic or whole-body approach to ensure patients receive the highest quality and quantity of cellular products available today.
Cellular Hope Institute will also be a center that will offer specialized regenerative medicine courses for physicians. Primarily, it is expected to be a resource center that will train doctors to incorporate modern regenerative medicine practices into their offices.
Our focus is to incorporate multiple specialties into separate programs within this training hub. Industry experts are expected to join the facility and offer the latest information about various compounds in the stem cell market, such as Mesenchymal stem cells, umbilical cord derived products, exosomes and many other stem cell products. We plan to target physicians who want to incorporate the treatment solutions into their practices, and the separate programs are designed to reach a wide array of practitioners.
In addition, Cellular Hope Institute also expects to have a fully functional manufacturing laboratory that seeks to elaborate the cellular products. The laboratory is already equipped with the latest and innovative technology to ensure it offers the best stem cell products and treatments. The facility will have enough capacity to store and distribute cellular products, including cells and exosomes. We expect it to be the primary supply center for doctors all over Mexico. The inauguration will mark a step closer to pursuing cell therapy, regenerative medicine, and modern tissue engineering options globally.
The opening of this center is an effort by Global stem Cells Group to continue its mission to reduce the suffering of patients and offer a new healing alternative. It is the commitment of scientists and doctors who believe in the potential of regenerative medicine as a standard treatment that should be in every doctor’s office worldwide.
To learn more about the cellular hope institute, visit its website here: https://cellularhopeinstitute.com/
- Published in Press Releases
Global Stem Cell Group Celebrates Success of ISSCA World Congress
The International Society of Stem Cell Applications (ISSCA) held its first World Congress on Regenerative Medicine at the Radisson Blu Hotel in Istanbul, Turkey between the 23rd and 26th of September, 2022. Like the previous events, the Congress brought together world-class physicians and scientists from over 35 countries, giving medical professionals access to first-rate live discussions, educational sessions, and intensive hands-on experience on regenerative medicine, cellular therapies, and all crucial topics in between.
Recognition Awards Were Presented
Announced in August 2022, the event was an immense success as it only spanned its prescheduled dates and had programs proceed accordingly. It featured an opening address from the President himself, Dr. Daeyong Kim, Ph.D., through which he recognized Mr. Salim Yildrim and Mr. Benito Novas with awards for their contribution to training and seminars held during the Covid-19 Pandemic. He also announced them as the hosts of the event.
The event was conducted at the Radisson Blu Hotel in Istanbul, Turkey. Including convenient breaks in between, its programs were split into 30 theoretical lectures for the first two days and two exclusive practice sessions on the third and fourth days.
With the Covid-19 pandemic further emphasizing the need for faster deployment of medical technologies, the theoretical lectures on the 23rd of September started with why and when Mesenchymal Stem Cells should be used for treatments.
On the first day, lectures featuring a progressive series of topics that define regenerative medicine were given. These included talks on:
- Clinical preconditioning for stem cells application;
- Stem cell and immunomodulation;
- The New era of regenerative medicine exosomes in clinical applications; and
- Plastic and reconstructive surgery guidelines and protocols for regenerative medicine & stem cell application.
Attendees were educated on cellular therapy on the second day, with speakers talking extensively on topics such as:
- Car-T cell therapy;
- Stem cell applications in ophthalmology;
- Ovarian regeneration: Treatment of female infertility using cellular therapies;
- Stem Cell therapy in systemic cardiomyopathy & heart failure; and
- The Multidisciplinary approach to ozone therapy.
At the close, both days accommodated additional abstract lectures from Dr. Serdar Kabataş, Dr. Erdinç Civelek, Dr. Erek Öztürk, and Dr. Eyüp Can Savrunlu. Although for attendees that opted for the two-day Conference package, the event had come to an end, they wouldn’t go home just yet.
A Sumptuous Gala Dinner Was Held
Everyone was treated to a gala dinner at the Old City Hotel at 360 Meze, Seres, Istanbul. This was a chance to meet the lecturers, physicians, and scientists in a less classroom-like environment and served as the perfect opportunity for networking and medical community building, just as the announcement promised.
The third day then welcomed members of the full-access program to a one-day hands-on training session held at the ReGen iC clinic.
Our program bestowed attendees with certificates of participation and membership, with training workshops championed by three ISSCA-certified physicians: Maritza Novas, the Director of Research and Development at Global Stem Cells Group, Miami, USA, Dr. Melihcan Sezgic, Regenerative Medicine Specialist and Surgeon, and Dr. Hilmi Karadeni̇z, Orthopedic doctor and specialist in sports medicine.
Open to only licensed physicians, practicals then concentrated on aesthetic and clinical applications of stem cell therapy. This included processes on cellular products, production, manufacturing and quality control, protocol discussion, and the application of protocols in live patients.
To cap it all off, Benito Novas, our Vice President and one of the awards recipients expressed his joy at the success of the ISSCA World Congress. He said, “It has been great meeting with worldclass doctors and scientists from different countries and having access to extensive practical experience in regenerative medicine and cellular therapies. You have all been generous in sharing your knowledge and experience in Regenerative Medicine. Truly, you have made this first ISSCA World Congress a success.”
The ISSCA successfully built on its bounce back events after a break caused by the pandemic. This was by presenting medical professionals globally with breakthrough updates on technologies, brands, and products for stem cell therapy, tissue engineering, and regenerative medicine in general. To learn more about the ISSCA, please visit https://www.issca.us/ or email us at info@stemcellsgroup.com.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in Press Releases
ISSCA Announces the Regenerative Medicine World Congress Speaker list and Promgram
The International Society for Stem Cell Application (ISSCA) has announced the Regenerative Medicine World Congress 2022 that will take place at the Radisson Blu Hotel in Istanbul, Turkey, between September 23rd and 25th, 2022. The congress brings together world-class doctors and scientists from over 35 countries.
Participants at the congress will have a rare chance to listen to over 25 world-leading medical experts as they make evidence-based research presentations on various issues related to stem cell therapy and regenerative medicine via evidence-based presentations.
Highlights of the Congress
Interactions with World-Class Speakers
Participants at the congress will have a chance to engage scientists and physicians with extensive experience applying cellular therapies and regenerative medicine in clinical environments. It will be an opportunity to gain insights into the industry and applications of this technology.
Updates on the Latest Products and Technologies in Regenerative Medicine
Some items to be discussed at the congress include new technologies, the latest products and equipment in regenerative medicine, and cellular studies. Participants will access these technologies and understand how they play a part in developing solutions to different problems in the medical field.
Hands-on Training by Leading Instructors
Participants will get two days of intensive training on clinical and aesthetic applications of stem cell therapy as part of the workshop. This training will be provided by ISSCA-certified instructors with experience in the particular areas that they will be handling. On the third day. participants will participate in live practical lessons on areas lectured on in the last two days. However, the practical lessons will be limited to 20 seats and available only to participants who purchase the all-access package.
An Opportunity to Network
Doctors and scientists will get an opportunity to network with like-minded professionals from different parts of the world to expand their knowledge and be part of a growing team of innovative minds who are leading the future of medicine. Participants will have the opportunity to interact, share ideas, and contact fellow professionals and speakers at the congress.
The Program
The president of ISSCA. Dr. Dayeong Kim (Korea). will open the program before the rest of the instructors take the stage. This team will tackle diverse areas that show the use of stem cell therapy in various medical conditions and real-world cases where the technology is being applied. Participants will get a chance to gain insights and expand their thoughts on the matters surrounding the use of stem cell technology to deal with various medical conditions.
Conference Packages
There are two packages for the conference. The first package will give participants access to two-day lectures on September 23rd and 24th. This package is going for $499.
The second package, dubbed “All-Access.” will include the one-day hands-on certification at ReGen iC Clinic on September 25th. in addition to two two-day lectures. This package will go for $950.
There are only 20 seats in the All-Access package. You can reserve a seat in either of the packages by purchasing the ticket on the ISSCA website.
More information regarding the conference can be found on the ISSCA website.
- Published in Press Releases
ISSCA Announces the Program Agenda of Regenerative Medicine World Congress 2022
The International Society for Stem Cell Application (ISSCA) is hosting the most anticipated regenerative medicine event of he year – Regenerative Medicine World Congress 2022. The congress will take place at the Radisson Blu Hotel Istanbul Sisli, Turkey, on September 23. 24. and 25.
The congress features theoretical lectures on the first two days. Physicians and scientists from around the world will present evidence-based research: demonstrate updates on technologies. products, and equipment: share their extensive experience in clinical applications of regenerative medicine and cellular therapies. 30 presentations focusing on stem cell research and regenerative medicine will be given by clinicians and researchers in different specialties. Featured topics include:
- Mesenchymal stem cells (MSC)
- Exosomes
- Plastic and reconstructive surgery
- Clinical trials
- Nerve injury treatment
- Applications in ophthalmology and cardiology
- Immunotherapy
The congress will be the ultimate gathering and a showcase of the most cutting-edge research in regenerative medicine. Congress participants will be able to network with like-minded medical professionals from different parts of the world and become part of a growing community leading the future of medicine.
With the All-Access package, congress participants will have access to the hands-on practice certification portion on the third day. The live practical portion has only 20 limited seats available.
ISSCA-certified instructors, Dr. Maritza Novas (Director of Research and Development at Global Stem Cells Group. USA) and Dr. Melihcan Sezgic (Plastic. Reconstructive and Aesthetic Surgeon. Regenerative Medicine Specialist. Turkey), will lead one-on-one training sessions at the ReGeniC Clinic. This is a great opportunity to gain intensive hands-on experience in the aesthetic and clinical applications of stem cell therapy. The following training modules are included:
Cellular Products
- Mononuclear layer umbilical cord blood
- Exosomes: Characterization, examination of growth factors and cytokines
- Amniotic fluid and its action as a natural anti-inflammatory
Production, Manufacturing, and Quality Control
- Eligibility and selection of donors
- Collection and management of samples
- Processing and laboratory standards
- Testing and validation of quality control
Protocol Discussion
- Clinical framework for therapeutic applications
- Protocol details and supporting scientific literature
- Product storage and preparation
- Selection of patients
- Results and expectations of patients
Application of the Protocol in Live Patients
- Demonstration of product preparation and injection
About ISSCA
The ISSCA is a multidisciplinary community of physicians and scientists with a mission to advance the science, technology, and practice of Regenerative Medicine to treat disease and lessen human suffering. Its members are leaders in setting standards and promoting excellence in regenerative medicine, related education, certification, research and publications.
The Regenerative Medicine World Congress 2022 will be one of the most celebrated events of the year. where we share the ISSCA values in Integrity, Interdisciplinary, and Innovation. The ISSCA invites physicians and healthcare professionals devoted to regenerative medicine to expand their network, access world-class speakers, and update themselves with the latest technologies, products and equipment.
For more information. please fill out the form to contact us.
- Published in Press Releases
How Exosome Therapy Differ from Stem Cell Therapy
Exosomes are potent microvesicles released by adult mesenchymal stem cells. They have the ability to help restore cells in the body by improving cell to cell communication.
Exosomes are not cells, and they are smaller than cells. When compared to adult stem cells, exosomes have much more growth factors which give them a better clinical and aesthetic potential than stem cells.
It’s a cell-free cell therapy, this makes it safer compared to other cellular therapy, because there’s no risk of rejection in graft Vs host.
Unlike some other cellular therapies, exosomes do not produce host graft reactions, because they do not carry HLA genetic information and are not cells but extracts of the cells (released by cells).
Exosomes have a superior regenerative capacity, because they are obtained from newborn umbilical cord tissue mesenchymal cells, which means they have not been exposed to any contaminating or toxic agent because our cells are as healthy as our body.
Exosomes improve the signaling between cells, thereby making them useful to revitalize, rejuvenate, restore, and cause anti-inflammatory effects in the body.
When compared to autologous adult stem cells, exosomes have much more healthy growth factors which gives them a better clinical and aesthetic potential than stem cells.
Exosomes are less complicated products to transport because the cells used in cellular therapy must be applied to the patient very quickly because they are live cells. In the laboratory, once they are thawed the doctors have limited time to apply them. However, with exosomes, they last longer, because as they are proteins they do not denature and can last for longer periods.
Exosomes is a superior product to autologous treatments because they do not require a surgical procedure, they come in a vial that can be injected directly, significantly reducing the risk and complications of a surgical procedure.
It is a superior product to autologous stem cell therapy because the patient’s cells have the same age and the same quality. For example, if a patient is a smoker and intoxicated, obviously the health of his cells is not the best. That is why the most indicated product is a donor product that is pure and free of toxins.
Mesenchymal cell-derived exosomes are preferably used in regenerative medicine. These cells are excellent regenerative cells due to their multipotent nature, therefore MSCs derived exosomes are superior to other exosomes products.
The Cellgenic lyophilized exosomes are derived from mesenchymal cells, which makes it superior to other exosome products, because mesenchymal cells have superior and excellent regenerative capacity.
This is why exosome therapy, especially Cellgenic lyophilized exosomes should be a doctor’s first choice.
- Published in Corporate News / Blog